Preoperative celecoxib use does not increase risk of myocardial infarction and may be protective against thromboembolic complications following total joint arthroplasty
Purpose: The purpose of this study was to determine if preoperative celecoxib treatment raises the risk of postoperative 1) myocardial infarctions, 2) thromboembolic complications, 3) acute kidney injuries, 4) transfusions, and 5) readmissions. Materials and methods: Using the administrative claims...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Journal of Orthopaedic Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2773157X24000687 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849388391792115712 |
|---|---|
| author | Matthew L. Magruder Shabnam Parsa Ariel N. Rodriguez Mitchell Ng Che Hang Jason Wong |
| author_facet | Matthew L. Magruder Shabnam Parsa Ariel N. Rodriguez Mitchell Ng Che Hang Jason Wong |
| author_sort | Matthew L. Magruder |
| collection | DOAJ |
| description | Purpose: The purpose of this study was to determine if preoperative celecoxib treatment raises the risk of postoperative 1) myocardial infarctions, 2) thromboembolic complications, 3) acute kidney injuries, 4) transfusions, and 5) readmissions. Materials and methods: Using the administrative claims database, PearlDiver, a retrospective study from January 2010 to October 2020 was conducted. Patients undergoing total knee or hip arthroplasty for osteoarthritis with recent celecoxib prescription were included, excluding those with MI history. Propensity score matched 230,587 patients (TKA: 38,433 celecoxib, 192,154 control; THA: 21,603 celecoxib, 108,008 control). Outcomes evaluated: 90-day myocardial infarction, DVT, PE, VTE, AKIs, transfusion, readmission. Multivariate logistic regression calculated odds ratios, 95 % CIs, p-values. Welch's t-tests assessed differences in stay lengths, costs (p < 0.001 threshold). Results: Celecoxib-treated patients showed comparable postoperative MI rates after TKA (0.16 % vs 0.23 %; OR 0.72; p = 0.018) and THA (0.25 % vs 0.22 %; OR 1.14; p = 0.359) versus controls. In TKA, celecoxib correlated with lower DVT (3.11 % vs 3.25 %; OR 0.95; p < 0.001) and transfusion (5.57 % vs 7.09 %; OR 0.76; p < 0.001) rates. PE (2.56 % vs 2.71 %; OR 0.94; p = 0.106), VTE (4.45 % vs 4.77 %; OR 0.93; p = 0.008), and readmission (5.35 % vs 5.39 %; OR 0.99; p = 0.73) showed no significant difference. In THA, celecoxib linked to lower DVT (2.57 % vs 3.02 %; OR 0.84; p < 0.001), VTE (3.64 % vs 4.30 %; OR 0.83; p < 0.001), transfusion (6.57 % vs 10.09 %; OR 0.65; p < 0.001), and readmission (5.49 % vs 6.06 %; OR 0.89; p = 0.001); PE (2.10 % vs 2.40 %; OR 0.87; p = 0.007) showed no significant difference. Conclusion: Celecoxib use showed no heightened risk of postoperative TKA and postoperative THA myocardial infarctions. Additionally, the celecoxib group exhibited notably reduced or insignificantly different rates of DVT, PE, VTE, transfusions, and readmissions. |
| format | Article |
| id | doaj-art-df80ba1d0f4f4b91886d013e51c24eb0 |
| institution | Kabale University |
| issn | 2773-157X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Orthopaedic Reports |
| spelling | doaj-art-df80ba1d0f4f4b91886d013e51c24eb02025-08-20T03:42:19ZengElsevierJournal of Orthopaedic Reports2773-157X2025-03-014110037310.1016/j.jorep.2024.100373Preoperative celecoxib use does not increase risk of myocardial infarction and may be protective against thromboembolic complications following total joint arthroplastyMatthew L. Magruder0Shabnam Parsa1Ariel N. Rodriguez2Mitchell Ng3Che Hang Jason Wong4Maimonides Medical Center, Department of Orthopaedic Surgery, Brooklyn, NY, USARenaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Corresponding author.Maimonides Medical Center, Department of Orthopaedic Surgery, Brooklyn, NY, USAMaimonides Medical Center, Department of Orthopaedic Surgery, Brooklyn, NY, USAMaimonides Medical Center, Department of Orthopaedic Surgery, Brooklyn, NY, USAPurpose: The purpose of this study was to determine if preoperative celecoxib treatment raises the risk of postoperative 1) myocardial infarctions, 2) thromboembolic complications, 3) acute kidney injuries, 4) transfusions, and 5) readmissions. Materials and methods: Using the administrative claims database, PearlDiver, a retrospective study from January 2010 to October 2020 was conducted. Patients undergoing total knee or hip arthroplasty for osteoarthritis with recent celecoxib prescription were included, excluding those with MI history. Propensity score matched 230,587 patients (TKA: 38,433 celecoxib, 192,154 control; THA: 21,603 celecoxib, 108,008 control). Outcomes evaluated: 90-day myocardial infarction, DVT, PE, VTE, AKIs, transfusion, readmission. Multivariate logistic regression calculated odds ratios, 95 % CIs, p-values. Welch's t-tests assessed differences in stay lengths, costs (p < 0.001 threshold). Results: Celecoxib-treated patients showed comparable postoperative MI rates after TKA (0.16 % vs 0.23 %; OR 0.72; p = 0.018) and THA (0.25 % vs 0.22 %; OR 1.14; p = 0.359) versus controls. In TKA, celecoxib correlated with lower DVT (3.11 % vs 3.25 %; OR 0.95; p < 0.001) and transfusion (5.57 % vs 7.09 %; OR 0.76; p < 0.001) rates. PE (2.56 % vs 2.71 %; OR 0.94; p = 0.106), VTE (4.45 % vs 4.77 %; OR 0.93; p = 0.008), and readmission (5.35 % vs 5.39 %; OR 0.99; p = 0.73) showed no significant difference. In THA, celecoxib linked to lower DVT (2.57 % vs 3.02 %; OR 0.84; p < 0.001), VTE (3.64 % vs 4.30 %; OR 0.83; p < 0.001), transfusion (6.57 % vs 10.09 %; OR 0.65; p < 0.001), and readmission (5.49 % vs 6.06 %; OR 0.89; p = 0.001); PE (2.10 % vs 2.40 %; OR 0.87; p = 0.007) showed no significant difference. Conclusion: Celecoxib use showed no heightened risk of postoperative TKA and postoperative THA myocardial infarctions. Additionally, the celecoxib group exhibited notably reduced or insignificantly different rates of DVT, PE, VTE, transfusions, and readmissions.http://www.sciencedirect.com/science/article/pii/S2773157X24000687CelecoxibTotal joint arthroplastyPostoperative complicationsMyocardial infarction |
| spellingShingle | Matthew L. Magruder Shabnam Parsa Ariel N. Rodriguez Mitchell Ng Che Hang Jason Wong Preoperative celecoxib use does not increase risk of myocardial infarction and may be protective against thromboembolic complications following total joint arthroplasty Journal of Orthopaedic Reports Celecoxib Total joint arthroplasty Postoperative complications Myocardial infarction |
| title | Preoperative celecoxib use does not increase risk of myocardial infarction and may be protective against thromboembolic complications following total joint arthroplasty |
| title_full | Preoperative celecoxib use does not increase risk of myocardial infarction and may be protective against thromboembolic complications following total joint arthroplasty |
| title_fullStr | Preoperative celecoxib use does not increase risk of myocardial infarction and may be protective against thromboembolic complications following total joint arthroplasty |
| title_full_unstemmed | Preoperative celecoxib use does not increase risk of myocardial infarction and may be protective against thromboembolic complications following total joint arthroplasty |
| title_short | Preoperative celecoxib use does not increase risk of myocardial infarction and may be protective against thromboembolic complications following total joint arthroplasty |
| title_sort | preoperative celecoxib use does not increase risk of myocardial infarction and may be protective against thromboembolic complications following total joint arthroplasty |
| topic | Celecoxib Total joint arthroplasty Postoperative complications Myocardial infarction |
| url | http://www.sciencedirect.com/science/article/pii/S2773157X24000687 |
| work_keys_str_mv | AT matthewlmagruder preoperativecelecoxibusedoesnotincreaseriskofmyocardialinfarctionandmaybeprotectiveagainstthromboemboliccomplicationsfollowingtotaljointarthroplasty AT shabnamparsa preoperativecelecoxibusedoesnotincreaseriskofmyocardialinfarctionandmaybeprotectiveagainstthromboemboliccomplicationsfollowingtotaljointarthroplasty AT arielnrodriguez preoperativecelecoxibusedoesnotincreaseriskofmyocardialinfarctionandmaybeprotectiveagainstthromboemboliccomplicationsfollowingtotaljointarthroplasty AT mitchellng preoperativecelecoxibusedoesnotincreaseriskofmyocardialinfarctionandmaybeprotectiveagainstthromboemboliccomplicationsfollowingtotaljointarthroplasty AT chehangjasonwong preoperativecelecoxibusedoesnotincreaseriskofmyocardialinfarctionandmaybeprotectiveagainstthromboemboliccomplicationsfollowingtotaljointarthroplasty |